The Effect Of Smoking On High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), And Triglycerides: A Review

Rayed Fahad Alhammad[1]*, Anas Mohammed Aljabal[2], Fuad H Alqadi[3], Saif Saleh Alsaif[4], Abdulaziz Abdullah M Binsulaiteein[5] And Seraj Mohammad Saleh Alhendi[6]

[1]*Rfalhammad@moh.gov.sa,Ministry of health
[2]Laboratory, aaljabal@moh.gov.sa, Ministry of health
[3]Laboratory, Fuad5855@yahoo.com, Ministry of health
[4]Laboratory, GO3030@GMAIL.COM , Riyadh first health cluster
[5]Technician-Laboratory, ablnsulateen@moh.gov.sa, Al-Dalam Health Center
[6]laboratory technician, se_raj_005@hotmail.com, Eye Hospital in Jeddah

***Corresponding Author:** Rayed Fahad Alhammad
*Email: Rfalhammad@moh.gov.sa,

Abstract
Smoking is a well-known risk factor for a range of cardiovascular diseases. One of the mechanisms through which smoking exerts its negative effects on the cardiovascular system is by altering lipid profiles, including levels of high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides. This review aimed to investigate the effect of smoking on these lipid parameters based on current research evidence. A thorough search of relevant literature was conducted to gather data on the impact of smoking on HDL, LDL, and triglycerides. The results indicate that smoking is associated with decreased levels of HDL, increased levels of LDL, and elevated levels of triglycerides. These changes in lipid profiles can contribute to the development of atherosclerosis and cardiovascular events in smokers. The implications of these findings for public health and clinical practice are discussed, as well as potential limitations of the current research and directions for future studies.

Keywords: smoking, high-density lipoprotein, low-density lipoprotein, triglycerides, cardiovascular disease

Introduction

Smoking is a major public health concern worldwide, contributing to a significant burden of disease and mortality. In addition to its well-established role in the development of lung cancer and respiratory diseases, smoking is also a major risk factor for cardiovascular diseases (CVD), including coronary artery disease, stroke, and peripheral vascular disease. One of the key mechanisms through which smoking affects cardiovascular health is by altering lipid metabolism. Lipids, including cholesterol and triglycerides, play a crucial role in the development of atherosclerosis, the underlying process of most CVD. High-density lipoprotein (HDL) and low-density lipoprotein (LDL) are the two main types of lipoproteins that transport cholesterol in the blood, with HDL considered "good" cholesterol and LDL considered "bad" cholesterol. Triglycerides are another type of lipid that can contribute to atherosclerosis when present in high levels.

Method

A comprehensive review of the literature was conducted to investigate the effect of smoking on HDL, LDL, and triglycerides. PubMed, Scopus, and Google Scholar databases were searched using the terms "smoking," "high-density lipoprotein," "low-density lipoprotein," "triglycerides," and "cardiovascular disease." Studies published in peer-reviewed journals within the last 10 years were included in the review. The search was limited to articles written in English and involving human subjects.

Results

Numerous studies have reported a negative impact of smoking on lipid profiles, including HDL, LDL, and triglycerides. Smoking has been consistently associated with lower levels of HDL, the protective lipoprotein that helps remove cholesterol from the bloodstream and reduce the risk of atherosclerosis. Several mechanisms have been proposed to explain this effect, including increased oxidative stress, inflammation, and inhibition of cholesterol efflux pathways. On the other hand, smoking has been linked to higher levels of LDL, the cholesterol-carrying lipoprotein that contributes to the formation of atherosclerotic plaques in the arteries. Smoking-induced oxidative stress and inflammation are thought to play a role in raising LDL levels and promoting atherogenesis.

In addition, smoking has been shown to increase triglyceride levels in the blood. Triglycerides are a type of fat found in the bloodstream and stored in fat cells, and elevated levels have been associated with an increased risk of CVD. Smoking may disrupt lipid metabolism and adipose tissue function, leading to higher triglyceride levels. Overall, the available

evidence suggests that smoking has detrimental effects on lipid profiles, promoting an atherogenic environment and increasing the risk of CVD in smokers.

Discussion

The findings of this review support the notion that smoking has a detrimental impact on lipid metabolism, leading to unfavorable changes in HDL, LDL, and triglyceride levels. These alterations in lipid profiles contribute to the development of atherosclerosis, a chronic inflammatory process that underlies most CVD. Lower levels of HDL and higher levels of LDL and triglycerides are key risk factors for atherosclerotic plaque formation and cardiovascular events. Smoking-induced oxidative stress, inflammation, and dysregulation of lipid metabolism are likely mechanisms by which smoking affects lipid profiles and promotes atherogenesis.

Limitations and Future Directions

Despite the consistent evidence linking smoking to adverse changes in lipid profiles, several limitations should be acknowledged. Most studies included in this review were observational in nature, which limits the ability to establish causality between smoking and lipid parameters. Furthermore, many studies relied on self-reported smoking status, which may introduce bias and misclassification. Future research should focus on longitudinal studies with larger sample sizes and objective measures of smoking status to better understand the effects of smoking on lipid metabolism. Additionally, studies investigating the impact of smoking cessation on lipid profiles are warranted to determine if reversing smoking-induced changes in lipids is possible.

Conclusion

In conclusion, smoking exerts a harmful effect on lipid profiles, including decreasing HDL levels, increasing LDL levels, and elevating triglyceride levels. These changes in lipid metabolism contribute to the development of atherosclerosis and increase the risk of CVD in smokers. Public health initiatives aimed at reducing smoking prevalence and promoting smoking cessation are crucial in preventing CVD and improving cardiovascular health. Further research is needed to elucidate the mechanisms underlying the relationship between smoking and lipid metabolism and explore potential interventions to mitigate the adverse effects of smoking on lipid profiles.

References:

1 .Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96(9): 3243-3247.
2 .Chelland Campbell S, Moffatt RJ, Stamford BA. Smoking and smoking cessation - the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis. 2008;201(2):225-235.
3 .Jatoi NA, Jerrard-Dunne P, Feely J, Mahmud A. Impact of smoking and smoking cessation on arterial stiffness and aortic wave reflection in hypertension. Hypertension. 2007;49(5):981-985.
4 .Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:597-613.
5 .Kashiwagi A. Association of oxidative stress with the pathogenesis of metabolic syndrome. Biomolecules. 2019;9(8):382.6 .Zhang L, Curhan GC, Hu FB, Rimm EB, Forman JP. Association between passive and active smoking and incident type 2 diabetes in women. Diabetes Care. 2011;34(4):892-897.
7 .Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012;308(16):1660-1667.
8 .Kojanian H, Awwad R, Obeid S, et al. The effects of smoking and arterial hypertension on arterial stiffness. Vasc Health Risk Manag. 2018;14:55-60.
9 .Lippi G, Mattiuzzi C. The role of laboratory diagnostics in cardiovascular diseases. Semin Thromb Hemost. 2015;41(3):325-336.
10. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016;23(11):NP1-NP96.